DOCSLIB.ORG

Laws and Regulations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Laws and Regulations E/NL . 1962/55 27 November 1962 UNITED NATIONS ENGLISH ONLY Original: FINNISH LAWS AND REGULATIONS PROMULGATED TO GIVE EFFECT TO THE PROVISIONS OF THE CONVENTION OF 13 JULY 1931 FOR LIMITING THE MANUFACTURE AND REGULATING THE DISTRIBUTION OF NARCOTIC DRUGS, AS AMENDED BY THE PROTOCOL OF 11 DECEMBER 1946 FINLAND Communicated by the Government of Finland NOTE BY THE SECRETARY-GENERAL -- In accordance with Article 21 of the Convention of 13 July 1931 for Limiting the Manufacture and Regulating the Distribution of Narcotic Drugs, as amended by the Protocol of 11 December 1946, the Secretary-General has the honour to communicate the following legislative text. "Suomen Asetuskokoelma", No. 217-221 E/NL.1962/55 No. 218 ORDER TO AMEND THE ORDER CONCERNING THE APPLICATION OP THE PROVISIONS OF THE INTERNATIONAL CONVENTIONS ON NARCOTIC DRUGS Helsinki, 21 April 1961 On the proposal of the Minister for-Internal Affairs, article 1 of the Order (61/57 of 1 February 19572/ concerning the application of the provisions of the international conventions on narcotic drugs, in the form in which that article appears in the Order (243/60) of 13 May 1960, is hereby amended to read as followst Article 1 Part B Group I. This group also includes the salts of the drugs of the group and all preparations containing drugs of the group or salts of such drugs even though these are not specifically mentioned. 2/ Alphacetylmethadol"^ alpha (3-acetcxy-6-dimethylainino-4,4-diphenyl-heptane) Alphameproctine (alpha r-3-ethyl-l-methyl—4—phenyl—4—propionoxypiperidine) Alphamethadol (alpha-6-dimethylaraino-4,4—diphenyl-3-heptanol) Alphaprodine (alpha-l,3-dinrathyl-4—pheny1-4—propionoxypiperidine) Allylprodine (3-alIyl-l-methyl—4-pheny1—4—propionoxypiperidine) Anileridine (l-(aminophenethyl)—4-phenylpiperidine-4—carboxylic acid ethyl ester) Aeetylmethadol (3-acetoxy-6-dimethylamino-4, 4—diphenylheptane) Benzethidine (1-(2-benzyloxyethyl)—4-phenvlpiperidine-4-carboxvlic acid ethyl ester) Benzylmorphine and other morphine ethers with the exception of codeine, ethylmorphine and pholcodine Betacetyimethadol (beta-3-acetoxy-6-dimethylamino—4,4—diphenylheptane Betameprodine (beta^3-ethyl-l-methyl-4—phenyl-4—propionoxvpiperidine) Betamethadol (beta-6-dimethylamino—4,4-diphenyl-3-heptanol) Note by the .Secretariatt E/NL.1957/112 ¥ Mute by the Secretariat! Proposed or recommended international non-proprietary name? of drugs are underlined. - 2 - Betaprodine (beta-l,3-d:Lmethyl-4-phenyl-4-propionoxypiperidine) Dextromoramide (d-2,2^iphei^l-3-m8thyl^4-morpholinobutyiylpyTrolidiiie) /~(+)-4-(2-methyl- 4—oxo-3,3-diphenyl-4— (l-pyrrolidinyl) butyl) morpholine/2/ Desomorphine (dihydrodeoxymorphine) and its esters Diampromide (N-(2-ft}-metbylphenetbylamino ) propyl)-propionanilide) Diacetylmorphine /Heroin/ by which is meant diacetylmorphine having the formula C21H23°5N ^17^17 (C2H3°^203N^ 811(1 other morphine esters Diethylthiambutene (3-diethylamino-l,l-di-(2,-thienyl)-l-butene) Diphenoxylate (1-(3-eyano-3.3-diphenylpropyl)—4—phenylpiperidine-4—carboxylic acid ethyl ester) Dihydromorphine and its esters Dimepheptanol, bemethadol (6-dimethylamino-4,4—diphenyl-3-heptanol) Dimenoxadol (2-dimethylaminoethyl-l-ethoxy-l.1-dipheavlacetate) Dimethylthiambutene (3-dimethylamino-l,l- «U-(2'-thienyl)-l-butene) Dioxaphetyl butyrate (ethyl—4-morpholino-2,2-diphenylbutyrate) Dipipanone (4t4—diphenyl-6-piperidino-3-heptanone) Ecgonine, by which is meant laevo-ecgonine (( oC )D20 = -45.6 in 5 per cent solution of water), of which the formula is CgH 0 NjHgO, and all the derivatives of laevo- ecgonine which might serve industrially for its recovery. Etoxeridine (l-(2-(2-hydroxyethoxy)-ethyl)-4—phenylpiperidine-4—carboxylic acid ethyl ester) Etonitazene (l-diethylaminoethyl-2-para-ethoxybenzyl-5-nitroben^imidazole) Ethylmethylthiambutene (3-etby lmethylamino-1,1-di-(2•-thienyl)-l-butene) Phenazocine (1.2t3i4.5t6-hexahydro-8-hydroxy-6,ll-dimethyl-3-phenethyl-2,6-methano-3- benzazocine) ^'-hydroxy-5,9-dimethyl-2-phenethyl-6,7-benzomorphaiy Phenadoxone (6-morpholino-4,4-diphenyl-3-heptanone) Phenampromide (N-(l-methyl-2-piperidinoethyl)propionanilide) Phenomorphan (3-hydroxy-N-phenethylmorphinan) Phenoperidine (l-(3-hydroxy-3-phenylpropyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester) Furethidine (l-(2-tetrahydrofurfuryloxyethyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester) Hydrocodone, hydrokon (dihydrocodeinone) and its esters and ester salts together with preparations containing these substances with the exception of pentetrazol- hydrocodone solutions containing not less than 10 per cent of pentetrazol and not more than 0.5 per cent of hydrocodone salts Hydroxypethidine. oxypetidin (l-methyl-4-(3-hydroxyphenyl)-piperidine-4-carboxylic acid ethyl ester) ^•^ta-hydroxyphenyl-l-methylpiperidine-4-carboxylic acid ethyl ester/ Hydromorphino1 (14-hydroxydihydromorphine) Hydromorphone (dihydromorphiinone) and.its esters Isomethadone (6-dimethylamino-5-methyl-4,4—diphenyl-3-hexanone) Ketobemidone (l-methyl-4—(3-hydroxyphenyl)-4-piperidyl ethyl ketone) /4—meta-hydroxyphenyl- l-methyl-4-propionylpiperidine7 Clonitazene (2-(para-chlorbenzyl)-l-diethylaminoethyl-5-nitrobenzimidazole) Cocaine, by which is meant methyl-benzoyl laevo-ecgonine ((o£)D 20° = -16.4° in C N} salts 20 per cent solution of chloroform), of which the formula is 17^21°4 of cocaine and preparations made directly from the coca leaf and containing more than 0.1 per cent of cocaine; preparations which are made from the<above-mentioned substances or preparations and which either contain more than 0.1 per cent of cocaine or are obtained by adding merely a liquid or solid inert substance; other esters of ecgonine and their salts and preparations containing these substances Levophenacylmorphan ((-)-3-hydroxy-N-phenacylmorphinan) Levomethorphan ((-)-3-methoxy-N-methylmorphinan) Note by the Secretariat? The words in square brackets have been inserted by the Secretariat. - 3 - Levomoramide ((-)-2,2-Hiifher^l-3-niethyl-^morpholinobutyxylpyTrolidine) /J-)-4—(2-methyl- 4-0X0-3,3-di(phenyl—4— (1-pyrrolidinyl )morpholine/ Levorphanol Levorphan ((-)-3-hydroxy-N-methylmorphinan) Methadone. (6-dimethylamino—4t4-diphenyl-3-heptanone) Metazocine (1,2,3,4,5,6-hexaiydro-8-hydroxy-3,6,ll-trimethyl-2,6-methanO-3-benzazocine) ^2'-hydroxy-2,5,9-trimethy1-6,7-benzomorphan/ Metopon (7-methyldihydromorphinone) and its esters ^-methyldihydromorpbdnone/ Methyldesorphine (6-methyl-delta—6-deoxymorphine) Methyldihydromorphine (6-methyldihydromorphine) Morpheridine (1-(2-morpholinoethyl)-4—phenylpiperidine-4—carboxylic aoid ethyl ester) Morphinef by which is meant the principal alkaloid of opium having the chemical formula C^^H^gO^Nj salts of opium and preparations made directly from raw or medicinal opium and containing more than 20 per cent of morphine (e.g., allaudan, laudotor, pantopon and staropon); preparations which are made from the above-mentioned substances or preparations and whioh either contain more than 0.2 per oent of morphine or are obtained by adding merely a liquid or st»iid inert substance Morphine-N-oxide and its derivatives and the other pentavalent nitrogen morphine derivatives Myrophine fayristylbenzylmorphine) Norlevorphanol ((-)-3-hydroxymorphinan) Normethadone (6-dimethylamino—4«4-diphenvl-3-hexanone) Normorphine (demethylmorphin) Oxycodone» oxikon (dihydrohydroxycodeinone) and its esters /l4-hydroxydihydrocodeinone/ Oxymorphone (dihydrohydroxymorphinone) /l4-hydroxydihydromorphinone7 Pethidine (l-methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester) Piminodine (4-phenyl-l-0-phenylaminopropyl)piperidine-4-carboxylic acid ethyl ester) Proheptazine (lt3-dimethyl-4-phenyl-4—propionoxyhexamethyleneimine) ^T,3-dimethyl-4- phenyl—4-pr.opi onoxyazacyc loheptane7 NProperidine (l-methyl—4—phenylpiperidine-4—carboxylic acid isopropyl ester) and other esters except pethidine Racemethorphan ((I)-3-methoxy-N-methylmorphinan) Racen^^ 4-0X0-3|3-diphenyl-4-(l-pyrrolidinyl) butyl)morpholine/ Racemorphan ((±)-3-hydroxy-N-methylmorphinan) Thebaine Thebacon (acetyldihydrocodeinone) and its esters Trimeperidine (1,2,5-trimethyl-4-phenyl-4-propionoxypiperidine) Group II. This group also includes the salts of the drugs of the group. Acetyldihydrocodeine Bihydrocodeine Ethylmorphine Pholcodine (morpholinylethylmorphine) Codeine (methylmorphine) Norcodeine (N-demethylated codeine) Propoxyphene (4-dimethylamino-3-methyl-l,2-diphenyl-2-propionoxybutane) Helsinki, 21 April 1961. URHO KEKKDNEN President of the Republic Eemil Luukka, Minister for Internal Affairs .
Load more

Recommended publications
  • A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L
    Hofstra Law Review Volume 18 | Issue 3 Article 10 1990 A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L. Galiber Follow this and additional works at: http://scholarlycommons.law.hofstra.edu/hlr Part of the Law Commons Recommended Citation Galiber, Joseph L. (1990) "A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation," Hofstra Law Review: Vol. 18: Iss. 3, Article 10. Available at: http://scholarlycommons.law.hofstra.edu/hlr/vol18/iss3/10 This document is brought to you for free and open access by Scholarly Commons at Hofstra Law. It has been accepted for inclusion in Hofstra Law Review by an authorized administrator of Scholarly Commons at Hofstra Law. For more information, please contact [email protected]. Galiber: A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with R A BILL TO REPEAL CRIMINAL DRUG LAWS: REPLACING PROHIBITION WITH REGULATION Joseph L. Galiber* Conventional wisdom obliges elected officials to beat the narcodrums loudly and incessantly, and to demand increasingly harsh criminal penalties for the sale and use of illegal drugs.' It is reasonable to wonder why I, a senator, would dare submit a bill2 to the New York State Legislature which would regulate all drugs cur- rently proscribed as illegal in precisely the same manner as alcohol.3 The short answer is that the use of the criminal law to control drug use has not, and never will, have anything more than a costly and marginal impact on drug consumption.4 Despite all the public hyperventilation, drug consumption remains a private, consensual * New York State Senator; B.A.
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]
  • CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun
    CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0024006 A1 Simon (43) Pub
    US 2004.0024006A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0024006 A1 Simon (43) Pub. Date: Feb. 5, 2004 (54) OPIOID PHARMACEUTICAL May 30, 1997, now abandoned, and which is a COMPOSITIONS continuation-in-part of application No. 08/643,775, filed on May 6, 1996, now abandoned. (76) Inventor: David Lew Simon, Mansfield Center, CT (US) Publication Classification Correspondence Address: (51) Int. Cl. ................................................ A61K 31/485 David L. Simon (52) U.S. Cl. .............................................................. 514/282 P.O. Box 618 100 Cemetery Road (57) ABSTRACT Mansfield Center, CT 06250 (US) The invention is directed in part to dosage forms comprising a combination of an analgesically effective amount of an (21) Appl. No.: 10/628,089 opioid agonist analgesic and a neutral receptor binding agent or a partial mu-opioid agonist, the neutral receptor binding (22) Filed: Jul. 25, 2003 agent or partial mu-opioid agonist being included in a ratio Related U.S. Application Data to the opioid agonist analgesic to provide a combination product which is analgesically effective when the combina (63) Continuation-in-part of application No. 10/306,657, tion is administered as prescribed, but which is leSS analge filed on Nov. 27, 2002, which is a continuation-in-part Sically effective or less rewarding when administered in of application No. 09/922,873, filed on Aug. 6, 2001, excess of prescription. Preferably, the combination product now Pat. No. 6,569,866, which is a continuation-in affects an opioid dependent individual differently from an part of application No. 09/152,834, filed on Sep.
    [Show full text]
  • Two Patterns of Narcotic Drug Addiction in the United States John C
    Journal of Criminal Law and Criminology Volume 56 Article 8 Issue 2 June Summer 1965 Two Patterns of Narcotic Drug Addiction in the United States John C. Ball Follow this and additional works at: https://scholarlycommons.law.northwestern.edu/jclc Part of the Criminal Law Commons, Criminology Commons, and the Criminology and Criminal Justice Commons Recommended Citation John C. Ball, Two Patterns of Narcotic Drug Addiction in the United States, 56 J. Crim. L. Criminology & Police Sci. 203 (1965) This Criminology is brought to you for free and open access by Northwestern University School of Law Scholarly Commons. It has been accepted for inclusion in Journal of Criminal Law and Criminology by an authorized editor of Northwestern University School of Law Scholarly Commons. RESEARCH REPORTS TWO PATTERNS OF NARCOTIC DRUG ADDICTION IN THE UNITED STATES JOHN C. BALL* Evidence from the present study and a review and has, in modern times, often reflected the tech- of the literature support the thesis that two quite nical and scientific advances in medicine and distinct patterns of narcotic drug addiction exist pharmacology with respect to the particular drug in the United States at the present time. One ad- taken and the means of administration employed diction pattern is followed by young heroin users by the user. Thus, the invention of the hypodermic who come predominantly from metropolitan cen- syringe facilitated both the medical and non- ters and are engaged in illegal endeavors. The other medical use of opiates in the United States after pattern is typified by the middle-aged southern 1856. The practice of opium smoking became white who uses morphine or paregoric and obtains somewhat of a vogue among the demi-monde of his drugs through legal or quasi-legal means.
    [Show full text]
  • Drugs of Abuseon September Archived 13-10048 No
    U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WWW.DEA.GOV 9, 2014 on September archived 13-10048 No. v. Stewart, in U.S. cited Drugs of2011 Abuse EDITION A DEA RESOURCE GUIDE V. Narcotics WHAT ARE NARCOTICS? Also known as “opioids,” the term "narcotic" comes from the Greek word for “stupor” and originally referred to a variety of substances that dulled the senses and relieved pain. Though some people still refer to all drugs as “narcot- ics,” today “narcotic” refers to opium, opium derivatives, and their semi-synthetic substitutes. A more current term for these drugs, with less uncertainty regarding its meaning, is “opioid.” Examples include the illicit drug heroin and pharmaceutical drugs like OxyContin®, Vicodin®, codeine, morphine, methadone and fentanyl. WHAT IS THEIR ORIGIN? The poppy papaver somniferum is the source for all natural opioids, whereas synthetic opioids are made entirely in a lab and include meperidine, fentanyl, and methadone. Semi-synthetic opioids are synthesized from naturally occurring opium products, such as morphine and codeine, and include heroin, oxycodone, hydrocodone, and hydromorphone. Teens can obtain narcotics from friends, family members, medicine cabinets, pharmacies, nursing 2014 homes, hospitals, hospices, doctors, and the Internet. 9, on September archived 13-10048 No. v. Stewart, in U.S. cited What are common street names? Street names for various narcotics/opioids include: ➔ Hillbilly Heroin, Lean or Purple Drank, OC, Ox, Oxy, Oxycotton, Sippin Syrup What are their forms? Narcotics/opioids come in various forms including: ➔ T ablets, capsules, skin patches, powder, chunks in varying colors (from white to shades of brown and black), liquid form for oral use and injection, syrups, suppositories, lollipops How are they abused? ➔ Narcotics/opioids can be swallowed, smoked, sniffed, or injected.
    [Show full text]
  • Morphine Receptors As Regulators of Adenylate Cyclase Activity (Neuroblastoma X Glioma Hybrid/Prostaglandin El/Narcotic Dependence) SHAIL K
    Proc. Nat. Acad. Sci. USA Vol. 72, No. 2, pp. 590-594, February 1975 Morphine Receptors as Regulators of Adenylate Cyclase Activity (neuroblastoma X glioma hybrid/prostaglandin El/narcotic dependence) SHAIL K. SHARMA*t, MARSHALL NIRENBERG*, AND WERNER A. KLEEt * Laboratory of Biochemical Genetics, National Heart and Lung Institute, and the t Laboratory of General and Comparative Biochemistry, National Institute of Mental Health, Bethesda, Maryland 20014 Contributed by Marshall Nirenberg, November 11, 1974 ABSTRACT Morphine inhibits adenylate cyclase (EC (7) and rat glioma clone C6BU-1 (8), derived from C6 (9). 4.6.1.1) activity of neuroblastoma X glioma hybrid cells. Cells were grown as described (1). The inhibition is stereospecific and is reversed by the antagonist, naloxone. The relative affinities of narcotics Assay of cAMP of Intact Cells. Confluent cells (3-4 mg of for the opiate receptor agree well with their effectiveness protein 60 min dish) were washed 3 times with 5 ml of medium as inhibitors of adenylate cyclase. Morphine-sensitive and A modified Eagle's medium with 25 mM Hepes -insensitive cell lines were found, and the degree of sensi- [Dulbecco's tivity was shown to be dependent upon the abundance of (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) pH narcotic receptors. Thus, morphine receptors are func- 7.4, instead of NaHCO3, adjusted to 340 mosmol/liter with tionally coupled to adenylate cyclase. A molecular mech- 1.1 g of NaCl/liter] and incubated with medium A plus 0.5 anism for narcotic addiction and tolerance is proposed. mM Ro20-1724 and 0.5 mM I13MX for 30 min at 37°.
    [Show full text]
  • Outline for Controlled Substances Program
    Environmental Health and Safety Controlled Substances Program Date of Issuance: Review Date: 10/1/2019 (no changes) 10/01/2018 Revision Number: Initial Prepared by: EH&S Table of Contents HEADINGS Introduction Applicability Responsibilities Registration Requirements Authorized Use Ordering/Purchasing Administering and Dispensing Inventory Procedures (Continuing Records) Security Disposal FORMS: Registering or renewing a DEA or state license (CMU) Controlled Substances Authorized users list (CMU) Employee questionnaire for those with access to controlled substances (CMU) Record of Form 222 use (Order form) (CMU) Records of Controlled Substance Purchases (CMU) Record of Controlled Substance Administering and dispensing (CMU) Controlled Substance Physical Inventory (CMU) DEA Registration of Persons doing research or analysis (Form 225) DEA Registration of Dispensers (Form 224) DEA Registration Instructional (Form 224 and 226 to renew) DEA Report of loss or theft (Form 106) DEA Report of drugs surrendered (From 41) DEA SCHEDULES: Schedule I Schedule II Schedule III Schedule IV Schedule V INTRODUCTION State and Federal regulations have been promulgated concerning the use and handling of US Department of Justice Drug Enforcement Administration (DEA) controlled substances. These regulations are in place to address materials which are or have the potential to be addictive or habit forming. These substances have been categorized into “schedules” that have been created by the DEA to reflect their level of concern. The “Carnegie Mellon University DEA Controlled Substances Program” is intended to ensure that Carnegie Mellon University is in compliance with our regulatory requirements. Required activities under the DEA include: 1. Registration of your work with the DEA and with Carnegie Mellon’s Department of Environmental Health and Safety (EH&S).
    [Show full text]
  • Chapter 329 [New] Uniform Controlled Substances Act
    CHAPTER 329 [NEW] UNIFORM CONTROLLED SUBSTANCES ACT Part I. General Provisions Section 329-1 Definitions 329-2 Hawaii advisory commission on drug abuse and controlled substances; number; appointment 329-3 Annual report 329-4 Duties of the commission Part II. Standards and Schedules 329-11 Authority to schedule controlled substances 329-12 Nomenclature 329-13 Schedule I tests 329-14 Schedule I 329-15 Schedule II tests 329-16 Schedule II 329-17 Schedule III Tests 329-18 Schedule III 329-19 Schedule IV tests 329-20 Schedule IV 329-21 Schedule V tests 329-22 Schedule V 329-23 Republishing and distribution of schedules Part III. Regulation of Manufacture, Distribution, Prescription, and Dispensing of Controlled Substances 329-31 Rules 329-31.5 Clinics 329-32 Registration requirements 329-33 Registration 329-34 Revocation and suspension of registration 329-35 Order to show cause 329-36 Records of registrants 329-37 Filing requirements 329-38 Prescriptions 329-39 Labels 329-40 Methadone treatment programs Part IV. Offenses and Penalties 329-41 Prohibited acts B-penalties 329-42 Prohibited acts C-penalties 329-43 Penalties under other laws 329-43.5 Prohibited acts related to drug paraphernalia Amended 0612 1 329-44 Notice of conviction to be sent to licensing board, department of commerce and consumer affairs 329-45 Repealed 329-46 Prohibited acts related to visits to more than one practitioner to obtain controlled substance prescriptions 329-49 Administrative penalties 329-50 Injunctive relief Part V. Enforcement and Administrative Provisions 329-51 Powers of enforcement personnel 329-52 Administrative inspections 329-53 Injunctions 329-54 Cooperative arrangements and confidentiality 329-55 Forfeitures 329-56 Burden of proof; liabilities 329-57 Judicial review 329-58 Education and research 329-59 Controlled substance registration revolving fund; established Part VI.
    [Show full text]
  • (2) Patent Application Publication (10) Pub. No.: US 2017/0020885 A1 Hsu (43) Pub
    US 20170020885A1 (19) United States (2) Patent Application Publication (10) Pub. No.: US 2017/0020885 A1 Hsu (43) Pub. Date: Jan. 26, 2017 (54) COMPOSITION COMPRISING A (52) U.S. CI. THERAPEUTIC AGENT AND A CPC ......... A61K 31/5377 (2013.01); A61K 9/0053 RESPIRATORY STIMULANT AND (2013.01); A61K 31/485 (2013.01); A61 K METHODS FOR THE USE THEREOF 9/5073 (2013.01); A61K 9/5047 (2013.01): A61K 45/06 (2013.01); A61K 9/0019 (71) Applicant: John Hsu, Rowland Heights, CA (US) (2013.01); A61K 9/209 (2013.01) (72) Inventor: John Hsu, Rowland Heights, CA (US) (57) ABSTRACT (21) Appl. No.: 15/214,421 (22) Filed: Jul. 19, 2016 The present disclosure provides a safe method for anesthesia or the treatment of pain by safely administering an amount Related U.S. Application Data of active agent to a patient while reducing the incidence or severity of suppressed respiration. The present disclosure (60) Provisional application No. 62/195,769, filed on Jul. provides a pharmaceutical composition comprising a thera 22, 2015. peutic agent and a chemoreceptor respiratory stimulant. In one aspect, the compositions oppose effects of respiratory Publication Classification suppressants by combining a chemoreceptor respiratory (51) Int. Cl. stimulant with an opioid receptor agonist or other respira A6 IK 31/5377 (2006.01) tory-depressing drug. The combination of the two chemical A6 IK 9/24 (2006.01) agents, that is, the therapeutic agent and the respiratory A6 IK 9/50 (2006.01) stimulant, may be herein described as the “drugs.” The A6 IK 45/06 (2006.01) present compositions may be used to treat acute and chronic A6 IK 9/00 (2006.01) pain, sleep apnea, and other conditions, leaving only non A6 IK 31/485 (2006.01) lethal side effects.
    [Show full text]
  • Decision of the Government of the Russian Federation No
    DECISION OF THE GOVERNMENT OF THE RUSSIAN FEDERATION NO. 681 OF JUNE 30, 1998 ON THE APPROVAL OF THE LIST OF NARCOTIC DRUGS, PSYCHOTROPIC SUBSTANCES AND THEIR PRECURSORS THAT SHALL BE SUBJECT TO CONTROL IN THE RUSSIAN FEDERATION In accordance with the Federal Law on Narcotic Drugs and Psychotropic Substances (Sobraniye zakonodatelstva Rossiyskoy Federatsii, 1998, No. 2, item 219) the Government of the Russian Federation resolves: To approve the annexed enumeration of narcotic drugs, psychotropic substances and their precursors that shall be subject to control in the Russian Federation. To establish that the amendment of the said enumeration shall be carried out on presentation of the Ministry of Public Health of the Russian Federation jointly with the Ministry of Internal Affairs of the Russian Federation. Chairman of the Government of the Russian Federation Sergey Kirienko Enumeration of Narcotic Drugs, Psychotropic Substances and Their Precursors That Shall Be Subject to Control in the Russian Federation (Approved by the Decision of the Government of the Russian Federation No. 681 of June 30, 1998) List of Narcotic Drugs and Psychotropic Substances Whose Circulation in the Russian Federation Is Prohibited in Accordance with the Legislation of the Russian Federation and the International Treaties of the Russian Federation (List I) List of Narcotic Drugs and Psychotropic Substances Whose Circulation in the Russian Federation Is Restricted and in Whose Respect Control Measures Shall Be Established in Accordance with the Legislation of
    [Show full text]